N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2, 2-dimethylpropanamide sulfate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2, 2-dimethylpropanamide sulfate
• 英文别名: N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropaneamide sulfate；N-(1-Octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.sulfate；N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate；N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfate；2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid;sulfuric acid
• 化学式: C₂₅H₄₀N₂O₃*H₂O₄S
• 分子量: 514.684
• InChiKey: PAXYOTBBFFQQTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.99
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  153
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  帕替麦布 在 硫酸 作用下， 以 水 、 丙酮 为溶剂， 以86%的产率得到N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2, 2-dimethylpropanamide sulfate
  参考文献：
  名称：

  EP1364942

  摘要：

  公开号：

文献信息

• Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：US06063806A1

  公开（公告）日：2000-05-16

  A heterocyclic derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

  公式(I)的杂环衍生物##STR1##及其药用盐。本发明的化合物(I)及其药用盐在哺乳动物中表现出优越的ACAT抑制活性和脂质过氧化抑制活性，并且可用作ACAT抑制剂和脂质过氧化抑制剂。具体而言，它们可用于动脉粥样硬化、高脂血症、糖尿病性动脉硬化以及脑血管和心血管缺血性疾病的预防和治疗。
• Indoline derivative and process for producing the same
  申请人：Tomori Hiroshi

  公开号：US20060014965A1

  公开（公告）日：2006-01-19

  The present invention provides novel synthetic intermediates for the production of indoline derivatives, which exhibit excellent ACAT inhibitory activity, and processes for the preparation thereof.

  本发明提供了一种生产吲哚啉衍生物的新型合成中间体，该衍生物具有出色的ACAT抑制活性，并提供其制备方法。
• MEDICINAL COMPOSITIONS
  申请人：Sankyo Company, Limited

  公开号：EP1314423A1

  公开（公告）日：2003-05-28

  The present invention provides a pharmaceutical composition for administering simultaneously, separately or sequentially N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and a HMG-CoA reductase inhibitor.

  本发明提供了一种药物组合物，用于同时、分别或依次给药 N-(1-辛基-5-羧甲基-4,6-二甲基吲哚啉-7-基)-2,2-二甲基丙酰胺或其药理上可接受的盐和 HMG-CoA 还原酶抑制剂。
• INDOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
  申请人：Sankyo Company, Limited

  公开号：EP1364942A1

  公开（公告）日：2003-11-26

  The present invention provides novel synthetic intermediates for the production of indoline derivatives, which exhibit excellent ACAT inhibitory activity, and processes for the preparation thereof.

  本发明提供了用于生产具有优异 ACAT 抑制活性的吲哚啉衍生物的新型合成中间体及其制备工艺。
• MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST
  申请人：Sankyo Company, Limited

  公开号：EP1421953A1

  公开（公告）日：2004-05-26

  The present invention relates to a pharmaceutical composition for administering simultaneously, separately or sequentially an angiotensin II receptor antagonist and an ACAT inhibitor.

  本发明涉及一种药物组合物，用于同时、分别或依次给药血管紧张素 II 受体拮抗剂和 ACAT 抑制剂。